Cordonnier Michael 4

4 · CARLSMED, INC. · Filed Mar 4, 2026

Form 4

Period: 2026-03-02

DirectorCEO, President

Transactions

Exercise/Conversion
Common Stock
2026-03-02$0.34/sh+197,855$66,281→ 1,554,501 total
Sale
Common Stock
[F1][F2]
2026-03-02$13.29/sh−197,855$2,629,889→ 1,356,646 total
Exercise/Conversion
Common Stock
2026-03-03$0.34/sh+160,567$53,790→ 1,517,213 total
Exercise/Conversion
Common Stock
2026-03-03$4.35/sh+33,264$144,765→ 1,550,477 total
Exercise/Conversion
Stock Option (Right to Buy)
[F3]
2026-03-02−197,855→ 160,567 total
Exercise: $0.34Exp: 2031-01-07→ Common Stock (197,855 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
[F3]
2026-03-03−160,567→ 0 total
Exercise: $0.34Exp: 2031-01-07→ Common Stock (160,567 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
[F4]
2026-03-03−33,264→ 191,692 total
Exercise: $4.35Exp: 2035-02-18→ Common Stock (33,264 underlying)

Footnotes (4)

[F1]Sale of shares to cover the exercise price, withholding tax obligations and broker fees and commissions, pursuant to a broker assisted cashless exercise of vested stock options granted on January 8, 2021 and February 19, 2025 under the Carlsmed, Inc. 2019 Stock Incentive Plan.
[F2]This transaction was executed in multiple trades at prices ranging from $13.000 to $14.030. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request, to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
[F3]25% of the shares underlying these options, representing a right to purchase a total of 358,422 shares, vested and became exercisable on December 15, 2021, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
[F4]25% of the shares underlying these options, representing a right to purchase a total of 224,956 shares, vested and became exercisable on December 15, 2025, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Signature

/s/ Michael Cordonnier|2026-03-04

Documents

1 file